Tarsons Products Limited has informed the Exchange about Transcript
TARSONS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tarsons Products submitted the transcript of its Q4 and FY25 earnings call held on May 29, 2025. For Q4 FY25, consolidated revenue grew 7% YoY to INR 113 crores, with consolidated EBITDA up 22.4% YoY and margin expanding 420 bps to 32.9%. Standalone EBITDA margin stood at 39.7% (up 60 bps). Full-year FY25 standalone revenue grew 13.3% to INR 314 crores, while consolidated revenue reached INR 392 crores including INR 78 crores from European subsidiary Nerbe. Domestic revenue grew 10% and international revenue 20% YoY. Management indicated the plastic labware industry is showing early signs of recovery, with the new Panchla facility's Phase 1 underway and cell culture production expected to begin in Q4 FY26, with full ramp-up in FY27-28. Peak utilization of INR 750-800 crores is expected by FY28-29, and standalone EBITDA margins could improve 2-3% as volumes grow.
The transcript offers a detailed view of Tarsons' growth path, with margin expansion and international growth as positives. However, consolidated net debt of INR 303 crores (peaking around INR 400 crores), higher depreciation of INR 80-85 crores expected in FY26, and Nerbe's low 7-8% margins dragging consolidated profitability remain near-term headwinds for shareholders.